Plus   Neg

OXiGENE Inc. (OXGN) Is Up Sharply On Orphan Drug Designation

OXiGENE Inc. (OXGN) announced after the close Thursday that the European Medicines Agency has granted orphan drug designation for ZYBRESTAT for the treatment of ovarian cancer.

OXiGENE gapped open sharply higher Friday and is now up 0.99 at $3.49 on above average volume. The stock has risen to over a 1-month high and has re-crossed its 50-day moving average.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT